(Boursier.com) — Abivax announces a transition in the chairmanship of its Board of Directors. Dr Philippe Pouletty, founder of Abivax and Chairman of the Board of Directors since its creation in 2013, informed the Board of his desire to henceforth devote his activity to other projects, including listed companies, and to no longer wish assume his responsibilities as Chairman. Consequently, Dr. Philippe Pouletty has informed the Board of Directors of his decision to resign as Chairman, effective immediately. However, after many years of leading the Board of Directors, Dr Pouletty will continue to support the development of the Company as a member of the Board of Directors.
Dr. Pouletty said: “I am proud that Abivax is one of the few biotechnology companies in Europe whose drug candidate, obefazimod (ABX464), is currently entering phase 3 clinical studies in order to meet the major medical needs in the field. chronic inflammatory diseases. Translating radical innovations, stemming from excellent academic research, into medicines for the benefit of patients has always been my major goal. I am confident that under his new chairmanship, Abivax will continue its activities successfully.”
Until the appointment of a new independent permanent Chairman, Ms. Corinna zur Bonsen-Thomas, an independent member of the Board of Directors of Abivax, will assume the role of interim Chairman. She has more than 30 years of high-level management experience, and has held various VP positions internationally in the pharmaceutical and medical device industries, as well as in healthcare startups. digital. She is co-founder and CEO of RetInSight, a company specializing in the digital health sector, and has over 15 years of experience as a member of Boards of Directors. Ms. zur Bonsen-Thomas has been a member of the Abivax Board of Directors since 2017.
©2022 Boursier.com